Characteristic distribution of maculopapular rash caused by gemcitabine‐based chemotherapy. Issue 2 (11th November 2020)

• Record Type: Journal Article
• Authors: Tohyama, Mikiko; Asagi, Akinori; Nakasya, Akio; Iuchi, Shunsuke; Hashine, Katsuyoshi
• Is Part Of: Journal of dermatology. Volume 48:Issue 2(2021)
• Page Start: 215
• Page End: 218
• Publication Date: 2020-11-11
• Subjects: combination chemotherapy -- gemcitabine -- maculopapular rash -- pancreatic neoplasms -- urological neoplasms; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.15654
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: Skin toxicity induced by gemcitabine, a chemotherapeutic agent, is not rare, but is usually mild. However, the occurrence of moderate to severe skin rash has been reported in patients treated with combinations of gemcitabine and other anticancer drugs. The aim of this study was to assess the characteristics of rash caused by gemcitabine‐based chemotherapy. We analyzed 12 patients who developed maculopapular rash over more than 10% of their body surface following gemcitabine‐based chemotherapy. Maculopapular rash appeared at 6.3 ± 1.3 days after the first administration in eight patients and the second administration in four patients. In two patients, the rash was localized on the lateral aspect of the trunk. The other 10 patients showed various degrees of rash on the chest and abdomen, in addition to the lateral aspect of the trunk. However, rash was absent on the upper and middle back in almost all patients. After the rash disappeared, gemcitabine was re‐administrated in eight patients. They continued the therapy with no or only mild rash relapse. In conclusion, maculopapular rash caused by gemcitabine‐based chemotherapy shows biased distribution to frontal and lateral sites of the trunk, which may be informative for consecutive chemotherapy.